Physician

Alan Scott Perlman, M.D.

According to 2025 Medicare claims, Alan Perlman, M.D. (NPI: 1114980448) practices nephrology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is THE ROGOSIN INSTITUTE, INC (NPI: 1821045170; TIN: 133184198) and primary practice location at 10019-3545.

Perlman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 410 traditional Medicare patients, billed 2,648 HCPCS/CPT codes, and received $139,131 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,717 prescription claims across 197 beneficiaries totaling $520,847 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 216 claims. Open Payments data shows 29 records totaling $34,639. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $92,029 and ending at $139,131. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $114,906 to $520,847. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,170 to $532.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	438	10,909	$92,029
2016	406	10,181	$83,711
2017	447	7,852	$106,534
2018	416	11,113	$108,675
2019	396	9,482	$111,205
2020	337	7,613	$87,822
2021	255	929	$78,740
2022	326	5,043	$111,148
2023	353	5,922	$114,570
2024	410	2,648	$139,131

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	79	948	$114,906
2016	99	1,066	$69,970
2017	89	977	$97,980
2018	81	961	$93,600
2019	92	978	$84,562
2020	85	855	$88,642
2021	112	843	$137,504
2022	153	1,067	$324,579
2023	191	1,245	$468,391
2024	197	1,717	$520,847

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	40	$1,923
2016	N/R	116	$4,824
2017	N/R	101	$4,732
2018	N/R	160	$6,108
2019	N/R	189	$11,194
2020	N/R	177	$7,822
2021	N/R	181	$6,925
2022	N/R	210	$5,541
2023	N/R	208	$5,962
2024	N/R	216	$5,334

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	61	61	$109
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	156	396	$103
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	147	288	$65
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	96	164	$41
36415	Insertion of needle into vein for collection of blood sample	141	298	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	176	12,455	$229,389
Kerendia	Finerenone	112	4,819	$97,719
Jardiance	Empagliflozin	53	2,790	$50,116
Lokelma	Sodium Zirconium Cyclosilicate	36	1,497	$36,328
Wegovy	Semaglutide	14	392	$18,452

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	13	$1,911
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	39	$830
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	61	$690
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	42	$678
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	16	$666

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	28	$34,639	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$13,138	Potrero Medical, Inc.

Explore More Providers

FAQ

What Medicare data is available for Alan Scott Perlman, M.D.?

Tedicare shows public-source Medicare data for Alan Scott Perlman, M.D. (NPI 1114980448), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Scott Perlman, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan Scott Perlman, M.D.?

Alan Scott Perlman, M.D. is linked to THE ROGOSIN INSTITUTE, INC (billing NPI 1821045170) in the available physician profile data.

Does Alan Scott Perlman, M.D. have Open Payments data?

Alan Scott Perlman, M.D. has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.